• Japanese
  • Korean
  • Chinese
Cover Image

PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013

Summary

GlobalData's "PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013" report, provides strategic analysis of the global generics industry. It discusses key trends, significant M&A deals in 2012, and describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of the top 30 companies into various markets, including the BRIC countries (Brazil, Russia, India, and China), to identify the top players in each market.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions

Scope

  • The report identifies the key generic players in various markets, including a special focus on emerging markets such as India, China, Russia, and Brazil.
  • Furthermore, it provides detailed analysis of the various generic markets including the US, Europe, APAC, and BRIC.
  • The report contains expert insights on the corporate strategies of generic companies seeking competitive advantage in the highly competitive generics industry.

Reasons to buy

  • Identify the key generic players in various markets, including the emerging markets such as India, China, Russia, and Brazil
  • Analyze and track the strategies that successful generic companies are using to gain share in the increasingly competitive market
  • Understand the key drivers and trends in the global generics industry
  • Use this information as an independent source for your due diligence and transaction strategy

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Upcoming Related Reports
  • 2.3. Recently Published Reports

3. Generics Industry Dynamics

  • 3.1. Generics to the Fore
    • 3.1.1. Imminence of the Patent Cliff
    • 3.1.2. Rising healthcare expenditures prompts many governments to resort to generics to save costs
    • 3.1.3. Focus on emerging markets
    • 3.1.4. Generic companies continuously drill holes in Big Pharma's deep pockets

4. Strategic Deals Trends

  • 4.1. Big Pharma's need to plug its revenue gap
  • 4.2. Governments cut healthcare spending as financial austerity spreads globally
  • 4.3. Low margins in the generics business necessitate scale economies
  • 4.4. Highlighted Deals from 2012
    • 4.4.1. Watson Closes $5.5KKKKK billion Purchase of Actavis
    • 4.4.2. Mylan Enters into Generics Partnership with Pfizer
    • 4.4.3. Merck and Supera Farma Laboratorios

5. Generics in North America

  • 5.1. Overview
  • 5.2. United States
    • 5.2.1. The US Pharmaceutical Industry
    • 5.2.2. Key Players
    • 5.2.3. Outlook

6. Generics in the Asia-Pacific (APAC)

  • 6.1. Overview
  • 6.2. Australia: Healthcare Policy Reform and the Generics Business
    • 6.2.1. Prescription Drug Regulation and Pricing in Australia
    • 6.2.2. The Australian Generics Business Environment
    • 6.2.3. Key Players
    • 6.2.4. Australia's Healthcare Reform and Impact on the Role of Generics
  • 6.3. Japan
    • 6.3.1. The Japanese Pharmaceutical Market
    • 6.3.2. Perception of Generics in Japan
    • 6.3.3. Impact of Pharmacies on Generics Substitution
    • 6.3.4. Generics Approval and Market Exclusivity
    • 6.3.5. Key Players

7. Generics in Europe and Africa

  • 7.1. Overview
  • 7.2. Europe
    • 7.2.1. The Increasing Burden on Healthcare
    • 7.2.2. Case Study: Germany
  • 7.3. Africa
    • 7.3.1. The Need for Local Production
    • 7.3.2. Low regulatory compliance and infrastructure result in a weak pharmaceutical industry
    • 7.3.3. Low standard of living makes medicines unaffordable, discouraging local players
    • 7.3.4. Global organizations and multinationals are standardizing Africa's pharmaceutical space
    • 7.3.5. Pharmaceutical Manufacturing Plan for Africa
    • 7.3.6. Case Study: South Africa

8. Generics in the BRIC Countries

  • 8.1. Overview
  • 8.2. Brazil
    • 8.2.1. Latin America Market Leader
    • 8.2.2. Government industrial policies will aid further development of the pharmaceutical industry
    • 8.2.3. Generics in Brazil
    • 8.2.4. Key Players
  • 8.3. Russia
    • 8.3.1. The New Federal Law on Health in the Russian Federation
    • 8.3.2. Pharma 2020KKKKK will further encourage domestic production in Russia
    • 8.3.3. Healthy financial situation places less pressure on the Russian government to reduce healthcare costs
    • 8.3.4. Key Player
  • 8.4. India
    • 8.4.1. Absence of product patents before 2005KKKKK triggered the birth of the Indian generics market
    • 8.4.2. Quality manufacturing facilities create an ideal environment for generics to thrive
    • 8.4.3. Inter-firm competition enables capabilities development
    • 8.4.4. Policies and initiatives encourage participation in generics manufacturing by driving demand
    • 8.4.5. Increased competition from larger multinationals may stymie the development of smaller domestic players
    • 8.4.6. Growing pressures on patent laws could challenge domestic generics manufacturers
    • 8.4.7. Key Market Players
    • 8.4.8. Outlook
  • 8.5. China
    • 8.5.1. Parallel demographics presents different scenarios on China's pharmaceutical industry
    • 8.5.2. A dysfunctional healthcare system provides little incentive for generics substitution
    • 8.5.3. Soaring healthcare expenditures pressure China's financial stability
    • 8.5.4. Healthcare reform will level the pharmaceutical industry playing field and foster the growth of the generics sector
    • 8.5.5. Key Players
    • 8.5.6. Market Outlook

9. Strategic Outlook

  • 9.1. Patent expiries and evolution of the regulatory landscape fuel generics
    • 9.1.1. US patent expiry wave presents a unique opportunity for generic manufacturers
    • 9.1.2. Government reforms will continue to facilitate generic prescribing
    • 9.1.3. Consolidation sweeps through the generics sector
    • 9.1.4. India's generic companies are an emerging force in the global generics market

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Research Methodology
    • 10.3.1. Coverage
    • 10.3.2. Secondary Research
    • 10.3.3. Expert Panel Validation
  • 10.4. About the Authors
    • 10.4.1. Analyst
    • 10.4.2. Director of Healthcare Industry Dynamics
    • 10.4.3. Global Head of Healthcare Research and Consulting
  • 10.5. About the Industry Dynamics Team
  • 10.6. About GlobalData
  • 10.7. Contact Us
  • 10.8. Disclosure Information
  • 10.9. Disclaimer

List of Tables

  • Table 1: First-Time Generic Drug Approvals, 2012
  • Table 2: Health Expenditures of OECD Countries as a Percentage of GDP, 2001-2010
  • Table 3: Recent and Upcoming US Patent Expirations, with FY2011 and FY2012 Sales Data
  • Table 4: Overview of the Collaboration and M&A Deals in this Report, 2012
  • Table 5: Watson Acquires Actavis in $5.5 Billion Deal
  • Table 6: Pfizer's Collaboration with Mylan Pharmaceuticals
  • Table 7: Merck's JV with Supera Farma Laboratorios
  • Table 8: Generics-Focused Deals by Major Drug Companies, 2008-2012
  • Table 9: Initial Phase of Price Reductions through Disclosure Agreements, 2009
  • Table 10: Top 10 Pharmaceutical Companies in Brazil, 1998 and 2007
  • Table 11: China: Urban and Rural Pharmaceutical Market Size, 2012

List of Figures

  • Figure 1: NME Approvals by the FDA, 1996-2012
  • Figure 2: Trend in Deals in the Generics Industry, 2008-2012
  • Figure 3: Pfizer: Emerging Markets Revenues as a Percentage of Annual Revenues, 2006-2012
  • Figure 4: Merck: Market focus1, 2007-2011
  • Figure 5: North American Generics Market Landscape - FY2012 Corporate Revenue Growth vs. North American Revenue Growth
  • Figure 6: Domestic Exports of Pharmaceutical Products from the US, 2000-2011
  • Figure 7: R&D Spending by PhRMA Members, 2004-2011
  • Figure 8: US Healthcare Expenditures and GDP, 2002-2011
  • Figure 9: US per Capita Healthcare Expenditures and GDP, 2001-2010
  • Figure 10: FDA Generic Drug Review Process
  • Figure 11: Generic Drug Approvals in the US, 2008-2012
  • Figure 12: APAC Generics Market Landscape - FY2012 Corporate Revenue Growth vs. APAC Revenue Growth
  • Figure 13: Australia: Trends in Prescription Volume and Government Costs, 2000-2011
  • Figure 14: Australian Government's and Patients' Contributions to PBS Costs, 2005-2011
  • Figure 15: Average Birth Life Expectancies1 in the APAC Region, 2012
  • Figure 16: EMEA Generics Market Landscape - FY2012 Corporate Revenue Growth vs. EMEA Revenue Growth
  • Figure 17: Birth Life Expectancies in Europe, 2010 vs. 2003
  • Figure 18: Public-Debt and Budget-Deficit-to-GDP Ratios in the Eurozone, 2012
  • Figure 19: Generics vs. Branded Products Split in South Africa, 2002-2006
  • Figure 20: Generics vs. Branded Products Split in South Africa, 2008-2012
  • Figure 21: Generics Utilization in South Africa, 2012-2020
  • Figure 22: BRIC Generics Market Landscape - FY2012 Corporate Revenue Growth vs. BRIC Revenue Growth
  • Figure 23: Russia, Percentage of Total Healthcare Expenditures by Revenue Source, 2009
  • Figure 24: Value of Pharmaceutical Exports from India, 2002-2011
  • Figure 25: Indian Generics Market Landscape - FY2012 Corporate Revenue Growth vs. India Revenue Growth
  • Figure 26: Total and Government Healthcare Expenditures* in China, 2001-2011
Show More
Pricing